Latest News

ChipCare Closes Oversubscribed $5 Million Series A Financing

With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries TORONTO, March 3, 2015 — C

Engineering innovations in Canada 2012

HIV testing produces results in minutes and is cheaper Portable lab device created by graduate researchers at the University of Toronto could radically change the treatment of HIV in de

HIV device

University of Toronto PhD candidate James Dou and Rakesh Nayyar, flow cytometry expert, discuss the newly developed portable cell analyzer, designed for on-the-spot blood tests, at thei

Innovation and collaboration bring student’s research idea on the national stage

After years of working in a lab, many students believe they may have a great idea, one that will change the world. But few have the know-how, passion and support to overcome the challen

Back To Top

The future of point-of-care diagnostics

  • The Problem

    In today’s global health, the biggest problem is lack of resources available to test and treat the great many diseases that inflict the sick and poor. Two key impediments to diagnosis and treatment remain to be resolved: in central labs and facilities, reducing cost while maintaining the same clinical standard; and in resource limited settings, mobile and distributed medical testing. In many diseases such as HIV/AIDS, malaria, tuberculosis, and cancer, currently there are very few diagnostic and monitoring tools available for delivering tests in a rapid, portable, and cost effective manner. These limitations often lead to a great human and financial burden to the healthcare system and a barrier to treatment.
  • The Solution

    ChipCare’s solution to this problem is an integrated point-of-care testing and monitoring system to address the current clinical challenges in both resource rich and resource limited settings. It combines patient identification, blood testing, communication, and external quality management protocol. It is also a platform system that can be used to test different diseases from a single drop of blood.
  • Competetive advantage

    ChipCare’s proprietary technology is based on a wide field imaging technique that can test multiple diseases from a single drop of blood. Currently no other POC device offers this functionality. ChipCare has developed a product roadmap which includes a pipeline of products (disposable test slides) to be rolled out after the initial T cell assay launch.

In the News

  • We look at the technology, the market and or social benefit. The benefit of this innovation is obvious -- it's going to help millions with HIV,

    Lino DeFacendis, Director at TIG
  • "This is a marvellous example of the benefits of research and through technology and knowledge transfer we are able to help launch this innovation for potential commercialization and global use by society."
    Paul Young, Professor, Vice-President (research)